{"id":105382,"date":"2025-10-27T08:11:56","date_gmt":"2025-10-27T13:11:56","guid":{"rendered":"https:\/\/www.erdheim-chester.org\/nuevas-esperanzas-en-la-terapia-dirigida-contra-la-histiocitosis\/"},"modified":"2025-10-27T08:41:19","modified_gmt":"2025-10-27T13:41:19","slug":"nuevas-esperanzas-en-la-terapia-dirigida-contra-la-histiocitosis","status":"publish","type":"post","link":"https:\/\/www.erdheim-chester.org\/es\/nuevas-esperanzas-en-la-terapia-dirigida-contra-la-histiocitosis\/","title":{"rendered":"Nuevas esperanzas en la terapia dirigida contra la histiocitosis"},"content":{"rendered":"<div>\n<p class=\"x_MsoNormal\"><span data-olk-copy-source=\"MessageBody\">Un nuevo estudio <b>del Memorial Sloan Kettering Cancer Center<\/b> destaca la promesa del <b>ulixertinib<\/b>, un f\u00e1rmaco de terapia dirigida que bloquea la ERK, para tratar ciertas formas de <b>histiocitosis,<\/b> incluida <b>la enfermedad de Erdheim-Chester (ECD<\/b>).<\/span><\/p>\n<p class=\"x_MsoNormal\">Dirigida por el Dr. Eli Diamond, miembro de la Junta M\u00e9dica Asesora del ECDGA, esta investigaci\u00f3n supone un emocionante paso adelante en el tratamiento de los trastornos histioc\u00edticos inducidos por MAPK. Para muchos miembros de nuestra comunidad, como Joey, miembro de la ECDGA cuyo viaje sigue inspir\u00e1ndonos, estos avances cient\u00edficos representan mucho m\u00e1s que un progreso cl\u00ednico. Ofrecen esperanza.  <\/p>\n<p class=\"x_MsoNormal\">Lee el art\u00edculo de MSKCC:<br \/>\n<a title=\"https:\/\/www.mskcc.org\/news\/targeted-therapy-drug-ulixertinib-for-histiocytosis-blood\" href=\"https:\/\/www.mskcc.org\/news\/targeted-therapy-drug-ulixertinib-for-histiocytosis-blood\" target=\"_blank\" rel=\"noopener\" data-auth=\"NotApplicable\" data-linkindex=\"2\">https:\/\/www.mskcc.org\/news\/targeted-therapy-drug-ulixertinib-for-histiocytosis-blood<\/a><\/p>\n<p class=\"x_MsoNormal\">Accede al art\u00edculo t\u00e9cnico completo en <i>Cancer Cell<\/i>:<br \/>\n<a title=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1535610825004064\" href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1535610825004064\" target=\"_blank\" rel=\"noopener\" data-auth=\"NotApplicable\" data-linkindex=\"3\">https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1535610825004064<\/a><\/p>\n<p class=\"x_MsoNormal\">En la ECDGA, estamos orgullosos de apoyar y compartir la investigaci\u00f3n que nos acerca a una mejor atenci\u00f3n, m\u00e1s respuestas y, alg\u00fan d\u00eda, una cura.<\/p>\n<p><em>La Erdheim-Chester Alianza Mundial contra las Enfermedades (ECDGA) no proporciona consejos m\u00e9dicos, diagn\u00f3sticos ni tratamientos. Todo el contenido es meramente informativo. Por favor, consulta con un profesional sanitario tus dudas m\u00e9dicas.  <\/em><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Un nuevo estudio del Memorial Sloan Kettering Cancer Center destaca la promesa del ulixertinib, un f\u00e1rmaco de terapia dirigida que bloquea la ERK, para tratar ciertas formas de histiocitosis, incluida la enfermedad de Erdheim-Chester (ECD).<\/p>\n","protected":false},"author":14,"featured_media":105377,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","_wds_title":"","_wds_metadesc":"","_wds_focus-keywords":"","_wds_meta-robots-adv":"","_wds_meta-robots-noindex":false,"_wds_meta-robots-nofollow":false,"_wds_meta-robots-index":false,"_wds_meta-robots-follow":false,"_wds_autolinks-exclude":false,"_wds_canonical":"","_wds_redirect":"","_wds_opengraph":[],"_wds_twitter":[],"cybocfi_hide_featured_image":"","wds_primary_category":0,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[391],"tags":[5126,3497,393,2634,5116,5112,1165,5118,5120,5122,5113,4335,5110,5124,4995],"class_list":["post-105382","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-ecdga-noticias","tag-avances-en-la-investigacion","tag-cancer-de-sangre-raro","tag-conciencia-dpi","tag-elidiamante","tag-enfermedad-de-erdheim-chester","tag-erkinhibidor","tag-histiocitosis","tag-mapkpathway","tag-memorialsloankettering","tag-precisionmedicina","tag-rarecancer","tag-rarediseaseresearch-es","tag-terapia-dirigida-2","tag-trastornos-histiociticos-2","tag-ulixertinib"],"_links":{"self":[{"href":"https:\/\/www.erdheim-chester.org\/es\/wp-json\/wp\/v2\/posts\/105382","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.erdheim-chester.org\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.erdheim-chester.org\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.erdheim-chester.org\/es\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.erdheim-chester.org\/es\/wp-json\/wp\/v2\/comments?post=105382"}],"version-history":[{"count":0,"href":"https:\/\/www.erdheim-chester.org\/es\/wp-json\/wp\/v2\/posts\/105382\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.erdheim-chester.org\/es\/wp-json\/wp\/v2\/media\/105377"}],"wp:attachment":[{"href":"https:\/\/www.erdheim-chester.org\/es\/wp-json\/wp\/v2\/media?parent=105382"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.erdheim-chester.org\/es\/wp-json\/wp\/v2\/categories?post=105382"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.erdheim-chester.org\/es\/wp-json\/wp\/v2\/tags?post=105382"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}